Clinical Trial Update: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 3F8/GM-CSF immunotherapy plus 13-cis-retinoic acid for consolidation in high-risk neuroblastoma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 13-cis-retinoic acid (13-cis-retinoic acid)
• 3F8
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: TERMINATED | Results posted: 2019-11-14